249
Participants
Start Date
April 9, 2018
Primary Completion Date
June 30, 2021
Study Completion Date
July 6, 2022
Tislelizumab
Administered intravenously
National Cheng Kung University Hospital, Tainan City
Hopital Larchet Chu Nice, Nice
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Istituto Clinico Humanitas, Rozzano
Universitatsklinikum Hamburg Eppendorf, Hamburg
Hospital Universitario La Paz, Madrid
Hospital Universitario Hm Madrid Sanchinarro, Madrid
Linkou Chang Gung Memorial Hospital, Taoyuan District
Groupe Hospitalier Du Haut Leveque, Pessac
Chu Montpellier Hopital Saint Eloi, Montpellier
Centre Eugene Marquis, Rennes
Centre Hospitalier Universitaire Nantes Hotel Dieu, Nantes
Kliniken Essen Mitte Evang Huyssens Stiftung, Essen
Klinikum Johannes Gutenberg Universitaet Mainz, Mainz
Azienda Ospedaliero Universitaria Pisana, Pisa
Hopital de La Croix Rousse, Lyon
E Da Hospital Kaohsiung, Kaohsiung City
Chu de Poitiers Site de La Mileterie, Poitiers
Hopital Beaujon, Clichy
Institut Gustave Roussy, Villejuif
Military Hospital of China, Beijing
Beijing Cancer Hospital, Beijing
Chinese Pla General Hospital, Beijing
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Affiliated Zhongshan Hospital of Fudan University, Shanghai
Xuzhou Central Hospital, Xuzhou
Anhui Provincial Hospital, Hefei
The Second Hospital of Anhui Medical University, Hefei
Weifang Peoples Hospital, Weifang
Tianjin Medical University Cancer Institute and Hospital, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang
The Second Affiliated Hospital of Nanchang University, Nanchang
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Hubei Cancer Hospital, Wuhan
Henan Cancer Hospital, Zhengzhou
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou
Nanfang Hospital of Southern Medical University, Guangzhou
Peking University Shenzhen Hospital, Shenzhen
Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Pastwowy Instytut Badawczy, Warsaw
Hospital Universitario Vall Dhebron, Barcelona
Ico Lhospitalet Hospital Duran I Reynals, Barcelona
Queen Elizabeth Hospital, Birmingham
The Christie Hospital, Greater Manchester
Royal Free Hospital London Nhs Trust, London
Kings College, London
Freeman Hospital, Newcastle upon Tyne
Lead Sponsor
BeiGene
INDUSTRY